慢性疼痛市場按藥物類別、適應症、用途、分銷管道和地區分類

2025 年全球慢性疼痛市場規模估計為 773 億美元，預計到 2032 年將達到 1,258.4 億美元，2025 年至 2032 年的年複合成長率（CAGR）為 7.2%。

圖。

慢性疼痛是指持續超過三個月或已超過正常癒合期的疼痛。許多疾病會引起慢性疼痛，包括關節炎、背痛、癌症、神經系統疾病和纖維肌痛。久坐的生活方式和日益增加的慢性疾病可能會增加全世界慢性疼痛的盛行率。慢性疼痛會限制活動能力和日常功能，對生活品質產生負面影響。全球慢性疼痛市場包括疼痛管理藥物、神經調節設備和其他治療方式，以減輕患者的痛苦並改善患者的治療效果。患有此類疾病的老年人口快速增加、醫療支出增加、新產品推出以及對管理選擇的認知不斷提高是推動市場成長的因素。

市場動態

慢性疾病和傷害的日益普及是導致全球慢性疼痛發病率上升的主要原因。這包括骨關節炎和背痛等肌肉骨骼疾病。易患此類疾病的老年人口不斷增加，將推動市場成長。此外，醫療支出的增加、新產品創新以及付款昂貴治療方案的能力也將推動市場成長。然而，學名藥等替代品的存在、違規以及某些治療方法的副作用可能會對市場參與企業造成挑戰。此外，新產品核可的監管障礙也可能阻礙市場成長。新興經濟體為產業參與企業提供了巨大的機會。疼痛治療方法技術的進步可能為市場成長開闢新的途徑。

研究的主要特點

本報告對全球慢性疼痛市場進行了詳細分析，並提供了預測期（2025-2032 年）的市場規模（十億美元）和年複合成長率（CAGR%），假設基準年為 2024 年。

它還強調了各個領域的潛在商機並說明了該市場的有吸引力的投資提案矩陣。

它還提供了對市場促進因素、限制因素、機會、新產品發布和核准、市場趨勢、區域前景以及主要企業採用的競爭策略的重要見解。

全球慢性疼痛市場的主要企業是根據公司亮點、產品系列、關鍵亮點、財務績效和策略等參數進行的分析。

研究涉及的主要企業包括輝瑞、禮來、葛蘭素史克、諾華、強生、阿斯特捷利康、普渡製藥、Endo Pharmaceuticals、Teva Pharmaceuticals Industries Ltd. 和 Mallinckrodt Pharmaceuticals。

本報告的見解將使負責人和企業經營團隊能夠就未來產品發布、新興趨勢、市場擴張和行銷策略做出明智的決策。

全球慢性疼痛市場報告迎合了該行業的各個相關人員，例如投資者、供應商、產品製造商、經銷商、新進業者和金融分析師。

相關人員將透過全球慢性疼痛市場分析中使用的各種策略矩陣更輕鬆地做出決策。

目錄

第1章 調查目的與前提條件

• 研究目標
• 先決條件
• 簡稱

第2章 市場展望

• 報告描述
  • 市場定義和範圍
• 執行摘要

第3章市場動態、法規與趨勢分析

• 市場動態
• 影響分析
• 監管情景
• 產品發布/核准
• PEST分析
• 波特分析
• 併購情景

4. 2020 年至 2032 年全球慢性疼痛市場（按藥物類別分類）（十億美元）

• 介紹
• 鴉片類藥物
• 非類固醇消炎劑(NSAID)
• 抗驚厥藥
• 抗憂鬱症
• 其他

5. 2020 年至 2032 年全球慢性疼痛市場（按適應症分類）（十億美元）

• 介紹
• 神經病變疼痛
• 關節炎疼痛
• 慢性背痛
• 癌症痛
• 偏頭痛
• 纖維肌痛
• 其他

6. 2020 年至 2032 年全球慢性疼痛市場（按應用分類）（十億美元）

• 介紹
• 肌肉骨骼
• 神經病變
• 腫瘤學
• 其他

7. 2020 年至 2032 年按分銷管道分類的全球慢性疼痛市場（十億美元）

• 介紹
• 醫院藥房
• 零售藥局
• 網路藥局

8. 2020 年至 2032 年全球慢性疼痛市場（按地區分類）（十億美元）

• 介紹
• 北美洲
• 拉丁美洲
• 歐洲
• 亞太地區
• 中東
• 非洲

第9章 競爭格局

• Pfizer Inc.
• Johnson & Johnson
• GlaxoSmithKline PLC
• Bayer AG
• Novartis AG
• Endo Pharmaceuticals
• Bristol-Myers Squibb
• Eli Lilly and Company
• Teva Pharmaceutical Industries Ltd.
• Reckitt Benckiser Group plc
• Medtronic plc
• AstraZeneca PLC
• Becton, Dickinson and Company
• AbbVie Inc.
• Horizon Therapeutics
• Mallinckrodt Pharmaceuticals
• Zynerba Pharmaceuticals
• Neurocrine Biosciences
• Sorrento Therapeutics
• Cypress Pharmaceutical

第 10 章分析師建議

• 興衰
• 一致的機會地圖

第 11 章 參考文獻與調查方法

• 參考
• 調查方法
• 關於出版商

Global Chronic Pain Market is estimated to be valued at USD 77.30 Bn in 2025 and is expected to reach USD 125.84 Bn by 2032, growing at a compound annual growth rate (CAGR) of 7.2% from 2025 to 2032.

Figure. Chronic Pain Market Share (%), By Region 2025

Chronic pain is defined as any pain lasting for more than three months or past the normal time of healing. The conditions that cause chronic pain are numerous and wide-ranging from arthritis, back pain, cancer, neurological disorders and fibromyalgia among others. Sedentary lifestyles and rising chronic diseases can increase the prevalence of chronic pain globally. It negatively impacts quality of life by limiting mobility and daily functioning. Global chronic pain market consists of drugs for pain management, neuromodulation devices, and other treatment modalities that provide relief and improve patient outcomes. Rapid growth in geriatric population who are more prone to such conditions, rise in healthcare expenditure, new product launches, and increasing awareness about management options can drive the market growth.

Market Dynamics:

Increasing prevalence of chronic diseases and injuries has significantly contributed to rising incidence of chronic pain worldwide. These include musculoskeletal disorders like osteoarthritis and lower back pain. Growing geriatric population who are more susceptible to such conditions can drive the market growth. Furthermore, greater healthcare spending, new product innovations, and ability to pay for expensive treatment options can also drive the market growth. However, presence of alternatives like generic drugs, non-compliance to medications, and side effects of certain therapies can pose challenges to market players. Moreover, regulatory hurdles for new product approvals can also hamper the market growth. Emerging economies provide major opportunities for industry players. Technological advancements in pain treatment modalities can open new avenues for the market growth.

Key features of the study:

This report provides in-depth analysis of the global chronic pain market, and provides market size (USD Billion) and compound annual growth rate (CAGR%) for the forecast period (2025-2032), considering 2024 as the base year

It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market

This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, market trends, regional outlook, and competitive strategies adopted by key players

It profiles key players in the global chronic pain market based on the following parameters - company highlights, products portfolio, key highlights, financial performance, and strategies

Key companies covered as a part of this study include Pfizer, Eli Lilly, GlaxoSmithKline, Novartis, Johnson & Johnson, AstraZeneca, Purdue Pharma, Endo Pharmaceuticals, Teva Pharmaceuticals Industries Ltd., and Mallinckrodt Pharmaceuticals

Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics

Global chronic pain market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts

Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global chronic pain market

Detailed Segmentation-

• By Drug Class Insights (Revenue, USD Bn, 2020 - 2032)
  • Opioids
  • Non-steroidal anti-inflammatory drugs (NSAIDS)
  • Anticonvulsants
  • Antidepressants
  • Others
• By Indication Insights (Revenue, USD Bn, 2020 - 2032)
  • Neuropathic pain
  • Arthritis pain
  • Chronic back pain
  • Cancer pain
  • Migraine
  • Fibromyalgia
  • Others
• By Application Insights (Revenue, USD Bn, 2020 - 2032)
  • Musculoskeletal
  • Neuropathy
  • Oncology
  • Others
• By Distribution Channel Insights (Revenue, USD Bn, 2020 - 2032)
  • Hospital Pharmacies
  • Retail Pharmacies
  • Online Pharmacies
• By Regional Insights (Revenue, USD Bn, 2020 - 2032)
  • North America
  • U.S.
  • Canada
  • Latin America
  • Brazil
  • Argentina
  • Mexico
  • Rest of Latin America
  • Europe
  • Germany
  • U.K.
  • Spain
  • France
  • Italy
  • Russia
  • Rest of Europe
  • Asia Pacific
  • China
  • India
  • Japan
  • Australia
  • South Korea
  • ASEAN
  • Rest of Asia Pacific
  • Middle East
  • GCC Countries
  • Israel
  • Rest of Middle East
  • Africa
  • South Africa
  • North Africa
  • Central Africa
• Key Players Insights
  • Pfizer Inc.
  • Johnson & Johnson
  • GlaxoSmithKline PLC
  • Bayer AG
  • Novartis AG
  • Endo Pharmaceuticals
  • Bristol-Myers Squibb
  • Eli Lilly and Company
  • Teva Pharmaceutical Industries Ltd.
  • Reckitt Benckiser Group plc
  • Medtronic plc
  • AstraZeneca PLC
  • Becton, Dickinson and Company
  • AbbVie Inc.
  • Horizon Therapeutics
  • Mallinckrodt Pharmaceuticals
  • Zynerba Pharmaceuticals
  • Neurocrine Biosciences
  • Sorrento Therapeutics
  • Cypress Pharmaceutical

Table of Contents

1. RESEARCH OBJECTIVES AND ASSUMPTIONS

• Research Objectives
• Assumptions
• Abbreviations

2. MARKET PURVIEW

• Report Description
  • Market Definition and Scope
• Executive Summary
  • Global Chronic Pain Market, By Drug Class
  • Global Chronic Pain Market, By Indication
  • Global Chronic Pain Market, By Application
  • Global Chronic Pain Market, By Distribution Channel
  • Global Chronic Pain Market, By Region

3. Market Dynamics, Regulations, and Trends Analysis

• Market Dynamics
• Impact Analysis
• Key Highlights
• Regulatory Scenario
• Product Launches/Approvals
• PEST Analysis
• PORTER's Analysis
• Merger and Acquisition Scenario

4. Global Chronic Pain Market, By Drug Class, 2020-2032, (USD Bn)

• Introduction
  • Market Share Analysis, 2025 and 2032 (%)
  • Y-o-Y Growth Analysis, 2021 - 2032
  • Segment Trends
• Opioids
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
• Non-steroidal anti-inflammatory drugs (NSAIDS)
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
• Anticonvulsants
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
• Antidepressants
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
• Others
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)

5. Global Chronic Pain Market, By Indication, 2020-2032, (USD Bn)

• Introduction
  • Market Share Analysis, 2025 and 2032 (%)
  • Y-o-Y Growth Analysis, 2021 - 2032
  • Segment Trends
• Neuropathic pain
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
• Arthritis pain
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
• Chronic back pain
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
• Cancer pain
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
• Migraine
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
• Fibromyalgia
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
• Others
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)

6. Global Chronic Pain Market, By Application, 2020-2032, (USD Bn)

• Introduction
  • Market Share Analysis, 2025 and 2032 (%)
  • Y-o-Y Growth Analysis, 2021 - 2032
  • Segment Trends
• Musculoskeletal
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
• Neuropathy
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
• Oncology
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
• Others
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)

7. Global Chronic Pain Market, By Distribution Channel, 2020-2032, (USD Bn)

• Introduction
  • Market Share Analysis, 2025 and 2032 (%)
  • Y-o-Y Growth Analysis, 2021 - 2032
  • Segment Trends
• Hospital Pharmacies
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
• Retail Pharmacies
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
• Online Pharmacies
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)

8. Global Chronic Pain Market, By Region, 2020 - 2032, (USD Bn)

• Introduction
  • Market Share (%) Analysis, 2025,2028 & 2032, (USD Bn)
  • Market Y-o-Y Growth Analysis (%), 2021 - 2032, (USD Bn)
  • Regional Trends
• North America
  • Introduction
  • Market Size and Forecast, By Drug Class, 2020 - 2032, (USD Bn)
  • Market Size and Forecast, By Indication, 2020 - 2032, (USD Bn)
  • Market Size and Forecast, By Application, 2020 - 2032, (USD Bn)
  • Market Size and Forecast, By Distribution Channel, 2020 - 2032, (USD Bn)
  • Market Size and Forecast, By Country, 2020 - 2032, (USD Bn)
    • U.S.
    • Canada
• Latin America
  • Introduction
  • Market Size and Forecast, By Drug Class, 2020 - 2032, (USD Bn)
  • Market Size and Forecast, By Indication, 2020 - 2032, (USD Bn)
  • Market Size and Forecast, By Application, 2020 - 2032, (USD Bn)
  • Market Size and Forecast, By Distribution Channel, 2020 - 2032, (USD Bn)
  • Market Size and Forecast, By Country, 2020 - 2032, (USD Bn)
    • Brazil
    • Argentina
    • Mexico
    • Rest of Latin America
• Europe
  • Introduction
  • Market Size and Forecast, By Drug Class, 2020 - 2032, (USD Bn)
  • Market Size and Forecast, By Indication, 2020 - 2032, (USD Bn)
  • Market Size and Forecast, By Application, 2020 - 2032, (USD Bn)
  • Market Size and Forecast, By Distribution Channel, 2020 - 2032, (USD Bn)
  • Market Size and Forecast, By Country, 2020 - 2032, (USD Bn)
    • Germany
    • U.K.
    • Spain
    • France
    • Italy
    • Russia
    • Rest of Europe
• Asia Pacific
  • Introduction
  • Market Size and Forecast, By Drug Class, 2020 - 2032, (USD Bn)
  • Market Size and Forecast, By Indication, 2020 - 2032, (USD Bn)
  • Market Size and Forecast, By Application, 2020 - 2032, (USD Bn)
  • Market Size and Forecast, By Distribution Channel, 2020 - 2032, (USD Bn)
  • Market Size and Forecast, By Country, 2020 - 2032, (USD Bn)
    • China
    • India
    • Japan
    • Australia
    • South Korea
    • ASEAN
    • Rest of Asia Pacific
• Middle East
  • Introduction
  • Market Size and Forecast, By Drug Class, 2020 - 2032, (USD Bn)
  • Market Size and Forecast, By Indication, 2020 - 2032, (USD Bn)
  • Market Size and Forecast, By Application, 2020 - 2032, (USD Bn)
  • Market Size and Forecast, By Distribution Channel, 2020 - 2032, (USD Bn)
  • Market Size and Forecast, By Country, 2020 - 2032, (USD Bn)
    • GCC Countries
    • Israel
    • Rest of Middle East
• Africa
  • Introduction
  • Market Size and Forecast, By Drug Class, 2020 - 2032, (USD Bn)
  • Market Size and Forecast, By Indication, 2020 - 2032, (USD Bn)
  • Market Size and Forecast, By Application, 2020 - 2032, (USD Bn)
  • Market Size and Forecast, By Distribution Channel, 2020 - 2032, (USD Bn)
  • Market Size and Forecast, By Country/Region, 2020 - 2032, (USD Bn)
    • South Africa
    • North Africa
    • Central Africa

9. Competitive Landscape

• Pfizer Inc.
  • Company Highlights
  • Product Portfolio
  • Key Developments
  • Financial Performance
  • Strategies
• Johnson & Johnson
  • Company Highlights
  • Product Portfolio
  • Key Developments
  • Financial Performance
  • Strategies
• GlaxoSmithKline PLC
  • Company Highlights
  • Product Portfolio
  • Key Developments
  • Financial Performance
  • Strategies
• Bayer AG
  • Company Highlights
  • Product Portfolio
  • Key Developments
  • Financial Performance
  • Strategies
• Novartis AG
  • Company Highlights
  • Product Portfolio
  • Key Developments
  • Financial Performance
  • Strategies
• Endo Pharmaceuticals
• Bristol-Myers Squibb
• Eli Lilly and Company
• Teva Pharmaceutical Industries Ltd.
• Reckitt Benckiser Group plc
• Medtronic plc
• AstraZeneca PLC
• Becton, Dickinson and Company
• AbbVie Inc.
• Horizon Therapeutics
• Mallinckrodt Pharmaceuticals
• Zynerba Pharmaceuticals
• Neurocrine Biosciences
• Sorrento Therapeutics
• Cypress Pharmaceutical

10. Analyst Recommendations

• Wheel of Fortune
• Analyst View
• Coherent Opportunity Map

11. References and Research Methodology

• References
• Research Methodology
• About us